Plain-English translation of NCT05784246 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ulcerative Colitis research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial tested mirikizumab, a new medication designed to treat moderate to severe ulcerative colitis in children and teens who had not responded well to other available treatments. The study examined whether the medication was effective, safe, and how the body processed it. Researchers gave participants the treatment intravenously (through an IV) or by injection under the skin, and measured how well it worked to control their ulcerative colitis symptoms.
Ulcerative colitis is a serious intestinal condition that affects some children and teens, and many of them do not get better with existing medications like steroids, biologics, or other immunosuppressive drugs. This trial was designed to test whether this new medication could help young patients whose disease was not controlled by these standard treatments.
Participants in this trial received the medication either through an IV infusion or as an injection under the skin, with doses adjusted based on their body weight. The trial examined how well the treatment controlled their ulcerative colitis symptoms, measured how their body processed the medication, and monitored them for any side effects. After completing the study, participants had the option to continue in a long-term follow-up study to see how the medication worked over time.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States